Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT06049290

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2025-12-04

342

Participants Needed

26

Research Sites

186 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a single-arm, open-label, multicenter, dose-escalation, and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and efficacy of LBL-034 in patients with Relapsed/Refractory Multiple Myeloma (R/R MM).

CONDITIONS

Official Title

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll in the study, and sign the written informed consent form
  • Age 18 years or older at the time of signing the informed consent
  • Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1
  • Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria
  • Have a life expectancy of at least 12 weeks
  • Fertile men and women of childbearing age willing to use effective contraception from consent until 6 months after last dose; women must have negative pregnancy test within 7 days before initial dose
Not Eligible

You will not qualify if you...

  • Major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to first dose, or require elective surgery during the trial
  • Use of immunomodulatory drugs within 14 days prior to first dose
  • Systemic corticosteroids or immunosuppressants within 14 days prior to first dose (topical or short-term preventive use excepted)
  • Active hepatitis B or C infection
  • Active infection requiring intravenous anti-infective therapy
  • History of immunodeficiency including HIV antibody positive
  • Pregnant or lactating women
  • Other conditions considered by investigator to affect compliance or suitability for study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 26 locations

1

The First Affiliated Hospital of Wannan Medical College

Wuhu, Anhui, China, 241001

Actively Recruiting

2

Peking University People's Hospital

Beijing, Beijing Municipality, China, 100044

Actively Recruiting

3

Peking University Shougang Hospital

Beijing, Beijing Municipality, China, 100144

Not Yet Recruiting

4

Fujian Medical University Union Hospital

Fuzhou, Fujian, China, 350000

Not Yet Recruiting

5

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China, 361000

Actively Recruiting

6

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China, 516000

Actively Recruiting

7

Shenzhen Second People's Hospital

Shenzhen, Guangdong, China, 518035

Actively Recruiting

8

The Afliliated Hospital of Guizhou Medical Univeristy

Guiyang, Guizhou, China, 563000

Actively Recruiting

9

The Second Affiliated Hospital of Hainan Medical University

Haikou, Hainan, China, 570000

Actively Recruiting

10

The First Affiliated Hospital of Henan University

Luoyang, Henan, China, 471003

Actively Recruiting

11

Henan Cancer Hospital

Zhengzhou, Henan, China, 450008

Not Yet Recruiting

12

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China, 450052

Not Yet Recruiting

13

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China, 430000

Actively Recruiting

14

Xiangya Hospital of Central South University

Changsha, Hunan, China, 410008

Not Yet Recruiting

15

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China, 215006

Not Yet Recruiting

16

The First Bethune Hospital of Jilin University

Changchun, Jilin, China, 130000

Actively Recruiting

17

Shengjing Hospital of China Medical University

Shengyang, Liaoning, China, 117004

Actively Recruiting

18

Qingdao Municipal Hospital

Qingdao, Shandong, China, 266011

Actively Recruiting

19

Shanghai Fourth People's Hospital

Shanghai, Shanghai Municipality, China, 200000

Not Yet Recruiting

20

Shanxi Bethune Hospital

Taiyuan, Shanxi, China, 030000

Actively Recruiting

21

The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)

Xi’an, Shanxi, China, 710004

Actively Recruiting

22

The First Affiliated Hospital of Xi'an Jiao Tong University

Xi’an, Shanxi, China, 710061

Not Yet Recruiting

23

Institute of hematology & blood diseases hospital, chinese academy of medical sciences & peking union medical college

Tianjin, Tianjin Municipality, China, 300000

Not Yet Recruiting

24

The First Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

25

The First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, China, 315000

Actively Recruiting

26

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China, 325000

Actively Recruiting

Loading map...

Research Team

J

jin lu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | DecenTrialz